In biotech and pharma, breakthrough science often captures the spotlight, but the ability to scale that science reliably, compliantly, and at speed is becoming the real differentiator. As the industry looks toward 2030, innovation will increasingly be defined by how well organizations integrate data, digital platforms, and supply chains into everyday decision-making. I spoke with Ankur Gupta, an executive transformation leader with experience across AI, quality, and global operations at Pfizer and Abbott Laboratories, to discuss where innovation truly emerges when execution, compliance, and scale are non-negotiable.

Ankur Gupta, Executive Transformation Leader, Former Pfizer and Former Abbot Laboratories

The Pulse: When people talk about biotech and pharma innovation, they often focus on R&D and pipelines. From your experience leading supply chain, IT, and quality transformations, where do you see the next wave of innovation coming from by 2030?

Ankur Gupta: When we discuss innovation in biotech and pharma, R&D should not be considered in isolation. We are entering an era where scientific breakthroughs are happening faster than our operating models can absorb them. Innovation will increasingly come from AI-enabled orchestration across development, manufacturing, quality and supply chain.

AI will play a big role here. Companies that can build intelligence and innovation into their DNA, with fewer handoffs and better data integrity, will outperform those that focus only on R&D and pipeline. It is anticipated that by 2030, the next wave of innovation will focus on how data is translated into rapid outcomes that are reliable, scalable, and compliant.

The Pulse: You’ve led major digital and ERP transformations in highly regulated environments. How should biotech and pharma leaders think differently about digital innovation when compliance, data integrity, and patient safety are non-negotiable?

AG: Mindset of treating compliance as an innovation inhibitor is outdated. By 2030, the most effective digital innovation will be built with compliance as a design principle, not a downstream control. What does that mean? – It means that, systems are auditable by default, data is traceable end-to-end, and AI (decision making) is transparent and explainable.

We’re already shifting from periodic validation to continuous assurance, and by 2030 that will be the norm. When digital platforms are designed and implemented correctly, they do not slow innovation but inherently make it safer and faster to scale. Regulators will ultimately reward compliance, clarity and control and appreciate rapid digitization that comes with thoughtful discipline.

The Pulse: Post-pandemic, supply chains have become a board-level priority. By 2030, what will distinguish resilient and innovative pharma supply chains from those that struggle?

AG: The pandemic in 2020 was a wake-up call. It exposed that many supply chains were fragile and optimized for efficiency. By 2030, resilient supply chains will be distinguished by decision intelligence, not just redundancy. Leaders will have real-time visibility into risk across suppliers, quality, logistics, and demand, and the ability to model tradeoffs before business disruption occurs.

The differentiator will be agility, adaptability and rapid data driven decision making. Companies that still rely on static forecasts and quarterly planning cycles will struggle. Those that embed AI-driven scenario planning into daily operations will respond faster, with less cost and less patient impact.

The Pulse: You’ve worked on reducing dependency on third-party logistics and rearchitecting global distribution models. How should pharma companies decide which capabilities must be owned internally versus outsourced as they plan for the next decade?

AG: This is an area where thinking has really evolved. Historically, outsourcing decisions were driven largely by cost. Going forward, that’s not enough. By 2030, pharma companies should own the fundamental capabilities related to business outcomes. That includes business strategy, process design, data platforms, quality governance, and supply chain orchestration.

For an AI enabled future, the foundational pillars for outsourcing should be control, learning, and decision rights. Execution capacity can and should be flexed through partners. The most resilient organizations will keep the brain in-house and use partners to extend reach.

The Pulse: With growing investments in data platforms, analytics, and AI, what are some of the elements that pharma companies should look out for make when trying to become ‘data-driven’?

AG: Many organizations confuse being data-rich with being data-driven. The best data driven organizations ensure that data integrity is maintained at rest and in transit. The most common mistake is investing in platforms before defining outcomes and decisions since data does not create value on its own.

By 2030, truly data-driven pharma companies will have to be explicit about which decisions are automated, which are augmented by AI, and which remain human-led. Data integrity, lineage, and trust will be non-negotiable for automation and AI enablement, especially in regulated environments. If data cannot be trusted it will lead to a wasted investment and even the best analytics platforms won’t deliver value.

The Pulse: Looking ahead to 2030, what skills or profiles do you believe biotech and pharma companies are underinvesting in today, particularly at the intersection of technology, quality, and operations?

AG: The talent gap will not just be technical but leadership capability. The most underinvested profiles will be leaders who have the overarching vision and can operate at the intersection of technology, quality, and operations simultaneously.

By 2030, we will need more digitally fluent & AI-literate operations and quality leaders. Organizations still structure technology, operations and quality separately, which creates friction and slows innovation. The future needs hybrid leaders who can bridge these domains and take accountability for outcomes, not just functions.

The Pulse: If you were advising the next generation of biotech and pharma leaders preparing for 2030, what is one hard-earned lesson from your career that you think is especially relevant for the decade ahead?

AG: The hardest lesson I have learned is that technology, by itself, does not transform organizations; timely and data-driven decisions do. AI will be pervasive by 2030. That is no longer the question. The real differentiator will be how decisively leaders use it to prioritize and to act with speed.

The leaders who succeed in the next decade will make tradeoffs explicit, simplify governance instead of hiding behind it, and hold themselves accountable for outcomes. Innovation rarely fails due to a lack of ideas. It fails because leaders delay hard decisions and avoid ownership and accountability.

The message is clear: by 2030, innovation in biotech and pharma will be defined not just by what is invented, but by how well organizations can operationalize science with speed, discipline, and accountability. Leaders who invest in decision intelligence, data integrity, and AI integrated operating models will be best positioned to turn breakthrough ideas into durable patient outcomes.